Details of the BTS
General Information of Binding Target of SBP (BTS) (ID: ST00016) | ||||||
---|---|---|---|---|---|---|
BTS Name |
CD276 antigen
|
|||||
Synonyms |
4Ig-B7-H3; B7 homolog 3; B7-H3; Costimulatory molecule; CD antigen CD276
|
|||||
BTS Type |
Protein
|
|||||
Family |
Immunoglobulin superfamily;
BTN/MOG family |
|||||
Gene Name |
CD276
|
|||||
Organism |
Homo sapiens (Human)
|
|||||
Function |
May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. Isoform 2 is shown to enhance the induction of cytotoxic T-cells and selectively stimulates interferon gamma production in the presence of T-cell receptor signaling.
|
|||||
UniProt ID | ||||||
UniProt Entry | ||||||
PFam | ||||||
Gene ID | ||||||
Sequence |
MLRRRGSPGMGVHVGAALGALWFCLTGALEVQVPEDPVVALVGTDATLCCSFSPEPGFSL
AQLNLIWQLTDTKQLVHSFAEGQDQGSAYANRTALFPDLLAQGNASLRLQRVRVADEGSF TCFVSIRDFGSAAVSLQVAAPYSKPSMTLEPNKDLRPGDTVTITCSSYQGYPEAEVFWQD GQGVPLTGNVTTSQMANEQGLFDVHSILRVVLGANGTYSCLVRNPVLQQDAHSSVTITPQ RSPTGAVEVQVPEDPVVALVGTDATLRCSFSPEPGFSLAQLNLIWQLTDTKQLVHSFTEG RDQGSAYANRTALFPDLLAQGNASLRLQRVRVADEGSFTCFVSIRDFGSAAVSLQVAAPY SKPSMTLEPNKDLRPGDTVTITCSSYRGYPEAEVFWQDGQGVPLTGNVTTSQMANEQGLF DVHSVLRVVLGANGTYSCLVRNPVLQQDAHGSVTITGQPMTFPPEALWVTVGLSVCLIAL LVALAFVCWRKIKQSCEEENAGAEDQDGEGEGSKTALQPLKHSDSKEDDGQEIA |
|||||
Sequence Length |
534
|
|||||
Synthetic Binding Protein (SBP) Targeting This BTS |
---|
SBP Name | Highest Status | Mechanism | Affinity | Application | Details | Ref |
---|---|---|---|---|---|---|
Affibody anti-CD276 AC12 | Research | Binder | Kd: 0.9 nM | Tumors [ICD-11: XH1N44] | [1] | |
Affibody anti-CD276 AC16 | Research | Binder | Kd: 20 nM | Tumors [ICD-11: XH1N44] | [1] | |
Affibody anti-CD276 AC9 | Research | Binder | Kd: 18 nM | Tumors [ICD-11: XH1N44] | [1] | |
DART Obrindatamab | Phase I; Discontinued | Binder | N.A. | B7-H3-positive tumors | [2] | |
References |
---|